Azora Therapeutics (NASDAQ: AZR) has announced the formation of a five-member board of directors comprising individuals with extensive drug development experience, a track record of FDA approvals, public-company governance expertise, and clinical capabilities in inflammatory bowel disease (IBD), gastroenterology, and immunology.
According to Azora, the new BOD members include: Matt Davidson, PhD, co-founder, president and CEO of Azora Therapeutics; Wendy Young, PhD, independent director, medicinal chemist and biotech leader with more than 30 years in drug discovery; Aida Habtezion, MD, independent director and physician-scientist in gastroenterology and immunology; Thomas Soloway, independent director and CEO of closely held T-knife Therapeutics; and Paul J. Hastings, independent director and CEO of Nkarta (NASDAQ: NKTX).
In a statement, Dr. Davidson commented, “The depth and diversity of expertise represented in our BOD position Azora for success in advancing AT177 into the clinic and through proof of concept as we aim to restore intestinal health for people living with ulcerative colitis. Their guidance and leadership will be invaluable in helping us execute our strategy to realize the full potential of AT177 and build value for shareholders.”
